105 search results for: burden of disease

ADVENT Forum 2025 On Demand page
On Demand
ADVENT Forum 2025 On Demand page

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

Atopic and Nonatopic Comorbidities in AD and the Importance <b>of</b> Early Intervention
Dermatology
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.

View more
Epidemiology and Pathophysiology <b>of</b> AD in Children
Dermatology
Epidemiology and Pathophysiology of AD in Children
expert video

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease

View more
CRSwNP at Center Stage: Impact <b>of</b> Biologics in Patients with Co-existing Type 2 Asthma
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
Type 2 Inflammation
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
expert video

Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.

View more
World Anosmia Awareness Day
On Demand
World Anosmia Awareness Day

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

Partnering With Patients: Scores That Matter in CRSwNP
Rhinology
Partnering With Patients: Scores That Matter in CRSwNP
interactivity

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

View more
Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP
Rhinology
Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP
videoanimation

Explore how type 2 inflammation drives sinonasal barrier dysfunction in chronic rhinosinusitis with nasal polyps (CRSwNP) with this video on the cellular mechanisms behind hallmark symptoms — including nasal congestion and loss of smell.

View more
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
Dermatology
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.

View more